Minor (1)glimepiride increases levels of tacrolimus by unknown mechanism. Modify Therapy/Monitor Closely. Monitor Closely (1)tipranavir, tacrolimus. Serious - Use Alternative (1)tacrolimus decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. Use Caution/Monitor. Comment: Coadministration of tacrolimus with cyclosporine may increase the risk of nephrotoxicity and immunosuppressive effects. Serious - Use Alternative (1)enzalutamide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. diflunisal, tacrolimus. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy . Contraindicated. Generic name: TACROLIMUS 0.5mg Avoid or Use Alternate Drug. . Monitor Closely (2)indinavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. pyrazinamide decreases levels of tacrolimus by unknown mechanism. Properly discard this product when it is expired or no longer needed. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Either increases levels of the other by decreasing metabolism. Use Caution/Monitor. Contraindicated (2)saquinavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider reducing dose when used concomitantly with lomitapide. Monitor Closely (2)tacrolimus and vorinostat both increase QTc interval. Modify Therapy/Monitor Closely. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. quercetin will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Serious - Use Alternative (1)eribulin and tacrolimus both increase QTc interval. Interactions listed are representative examples and do not include all possible clinical examples. Monitor Closely (1)erythromycin base will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. golimumab and tacrolimus both increase immunosuppressive effects; risk of infection. Serious - Use Alternative (2)tacrolimus and anagrelide both increase QTc interval. Use Caution/Monitor. Either increases effects of the other by immunosuppressive effects; risk of infection. Monitor Closely (2)nilotinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimus will increase the level or effect of aliskiren by P-glycoprotein (MDR1) efflux transporter. nefazodone will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. acyclovir and tacrolimus both increase nephrotoxicity and/or ototoxicity. clotrimazole will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Serious - Use Alternative (2)ceritinib increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methotrexate and tacrolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor.Minor (1)fludrocortisone, tacrolimus. tacrolimus and gemtuzumab both increase QTc interval. Contraindicated. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use caution when switching patients from long-acting therapies with immune effects. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine. Either increases effects of the other by QTc interval. Monitor Closely (1)clotrimazole will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. Avoid or Use Alternate Drug. ustekinumab, tacrolimus. Adjust dose when appropriate. Minor/Significance Unknown. Monitor Closely (1)larotrectinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimus increases levels of peramivir by decreasing renal clearance. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure. pacritinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Other (see comment). Monitor Closely (1)dupilumab, tacrolimus. Use Caution/Monitor. Monitor Closely (1)duvelisib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ezogabine, tacrolimus. alefacept and tacrolimus both increase immunosuppressive effects; risk of infection. tacrolimus decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Serious - Use Alternative (1)tacrolimus decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Monitor Closely (1)tacrolimus and levofloxacin both increase QTc interval. Minor (1)triamcinolone acetonide injectable suspension, tacrolimus. Modify Therapy/Monitor Closely. turmeric will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Monitor Closely (2)voclosporin and tacrolimus both increase serum potassium. Tecovirimat is a weak CYP3A4 inducer. The typical dose for once-daily Cialis for ED is 2.5 milligrams (mg) to 5 mg. oxcarbazepine will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Frequently monitor tacrolimus whole blood concentrations, renal function, and tacrolimus-associated adverse events if coadministered with elbasvir/grazoprevir. degarelix and tacrolimus both increase QTc interval. Minor/Significance Unknown. Monitor Closely (1)tacrolimus will increase the level or effect of paclitaxel by P-glycoprotein (MDR1) efflux transporter. Contraindicated. buprenorphine buccal and tacrolimus both increase QTc interval. Serious - Use Alternative (1)tacrolimus and vemurafenib both increase QTc interval. Contraindicated. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations. fluoxymesterone increases effects of tacrolimus by decreasing metabolism. indinavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Comment: Concomitant administration increases risk of nephrotoxicity. Use Caution/Monitor. Use Caution/Monitor. glimepiride increases levels of tacrolimus by unknown mechanism. Dexlansoprazole and tacrolimus compete for CYP2C19 metabolism. Comment: Concomitant administration increases risk of nephrotoxicity. cortisone, tacrolimus. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)aprepitant will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydroxychloroquine sulfate and tacrolimus both increase immunosuppressive effects; risk of infection. Minor/Significance Unknown. Avoid or Use Alternate Drug. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. tacrolimus and potassium citrate/citric acid both increase serum potassium. etodolac, tacrolimus. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid. Avoid or Use Alternate Drug. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. Serious - Use Alternative (1)ketorolac, tacrolimus. Use Caution/Monitor. Prograf is an immunosuppressive agent that is used to suppress the immune system of a patient who has received an organ from a donor. If concomitant use is unavoidable, increase CYP3A substrate dosage in accordance with approved product labeling. Either increases levels of the other by decreasing metabolism. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Use Caution/Monitor. Use Caution/Monitor.dichlorphenamide, tacrolimus. Avoid or Use Alternate Drug. pitolisant will decrease the level or effect of tacrolimus by Other (see comment). If used for liver transplant immunosuppression (Zortress), reduce tacrolimus dose and use target serum concentration to reduce nephrotoxicity. QTc prolongation reported with higher than recommended doses of fostemsavir. Monitor Closely (1)tacrolimus, ospemifene. erdafitinib, tacrolimus. Monitor Closely (1)tacrolimus and bedaquiline both increase QTc interval. Metoclopramide may increase the absorption of tacrolimus. Avoid or Use Alternate Drug. Use Caution/Monitor. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Serious - Use Alternative (1)tolmetin, tacrolimus. Modify Therapy/Monitor Closely. Other (see comment). tacrolimus decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Monitor Closely (2)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant therapy is expected to increase the risk of immunosuppression. It works by decreasing the activity of the immune system (defence system rejecting foreign substances) and helps in preventing the rejection of the transplanted organ by the body. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. Use Caution/Monitor. ketoconazole will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimus decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Use Caution/Monitor. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. lapatinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Table 1. Monitor Closely (1)tacrolimus and fluoxetine both increase QTc interval. Use Caution/Monitor. Use Caution/Monitor. eluxadoline increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Following an organ transplant, our body's immune system will try to reject the new organ. nefazodone will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. This drug is available at a higher level co-pay. Modify Therapy/Monitor Closely. Use Caution/Monitor. Serious - Use Alternative (1)antithymocyte globulin rabbit and tacrolimus both increase immunosuppressive effects; risk of infection. Serious - Use Alternative (1)buprenorphine transdermal and tacrolimus both increase QTc interval. Modify Therapy/Monitor Closely. encorafenib, tacrolimus. darunavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concurrent use of CYP3A substrates known to have narrow therapeutic indices or substrates primarily metabolized by CYP3A during treatment with ceritinib; if use of these medications is unavoidable, consider dose. conivaptan will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Immunosuppressants also increase risk of infection with concomitant live vaccines. Serious - Use Alternative (1)tacrolimus decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. tacrolimus will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. . Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Monitor Closely (1)teclistamab will increase the level or effect of tacrolimus by altering metabolism. Use Caution/Monitor. Monitor Closely (1)darunavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored. Use Caution/Monitor. Comment: Myelosuppressive agents can produce additive myelosuppression. Immunosuppressive drugs may reduce the immune response to influenza vaccine. tacrolimus and quinine both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. arformoterol and tacrolimus both increase QTc interval. Use Caution/Monitor.tacrolimus will increase the level or effect of cortisone by P-glycoprotein (MDR1) efflux transporter. dabrafenib will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Monitor Closely (2)budesonide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)griseofulvin will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided. Your doctor may control your blood pressure with medication.Tacrolimus may cause diabetes. tacrolimus and olaparib both increase pharmacodynamic synergism. If patients are able to tolerate oral therapy, the recommended oral starting doses should be initiated. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine. Monitor Closely (1)lansoprazole will increase the level or effect of tacrolimus by affecting hepatic enzyme CYP2C19 metabolism. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval. Use Caution/Monitor.lapatinib will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. tacrolimus will increase the level or effect of dabigatran by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Use Caution/Monitor. tacrolimus will increase the level or effect of deflazacort by P-glycoprotein (MDR1) efflux transporter. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Modify Therapy/Monitor Closely. ixekizumab, tacrolimus. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Monitor Closely (1)rifapentine will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)grapefruit will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. Serious - Use Alternative (2)tacrolimus and asenapine both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. Dose adjustment may be required with strong P-gp inhibitors. Avoid or Use Alternate Drug.St John's Wort decreases levels of tacrolimus by increasing metabolism. ), PVC-free tubing should likewise be used to minimize the potential for significant drug adsorption onto the tubing. solifenacin and tacrolimus both increase QTc interval. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered with palbociclib. Avoid or Use Alternate Drug. Serious - Use Alternative (1)buprenorphine subdermal implant and tacrolimus both increase QTc interval. Serious - Use Alternative (1)tacrolimus and procainamide both increase QTc interval. siponimod and tacrolimus both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, normalizing the formation of CYP450 enzymes. If unable to avoid, decrease tacrolimus dose by one-third. Use Caution/Monitor. Adults: Dosage is 0.1 - 0.2 mg/kg/day. tacrolimus will increase the level or effect of vinblastine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. omaveloxolone will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rabeprazole will increase the level or effect of tacrolimus by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. This has not been confirmed in vivo. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations.letermovir increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor.verapamil will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)tacrolimus increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Adjust dosage of CYP3A4 substrates, if clinically indicated. Use Caution/Monitor. Monitor Closely (1)tacrolimus will increase the level or effect of irinotecan liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. tacrolimus will increase the level or effect of loratadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. This effect may increase your risk of developing an infection or certain types of cancer (such as skin cancer, lymphoma). Monitor Closely (1)tacrolimus will increase the level or effect of bazedoxifene/conjugated estrogens by P-glycoprotein (MDR1) efflux transporter. Serious - Use Alternative (1)tacrolimus and temsirolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Serious - Use Alternative (1)glatiramer and tacrolimus both increase immunosuppressive effects; risk of infection. Monitor Closely (1)eluxadoline increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Contraindicated. Monitor Closely (1)bromocriptine increases levels of tacrolimus by decreasing metabolism. Use Caution/Monitor. Serious - Use Alternative (1)isoflurane and tacrolimus both increase QTc interval. tacrolimus will increase the level or effect of daunorubicin by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)rufinamide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of CYP substrate drug as needed. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)hydroxyzine and tacrolimus both increase QTc interval. cimetidine will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. trazodone will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Concurrent use of tacrolimus and mTOR inhibitors may contribute to the risk of TMA, Risk of posttransplant diabetes mellitus, especially in black and Hispanic patients; may occur in patients without pretransplant history of diabetes mellitus, Black patients may require higher doses in kidney transplant, Discontinue cyclosporine 24 hours before starting tacrolimus, Use with strong CYP3A inhibitors and inducers: a rapid, sharp rise in tacrolimus levels reported after co-administration with a strong CYP3A4 inhibitor, clarithromycin, despite an initial reduction of tacrolimus dose; early and frequent monitoring of tacrolimus whole blood trough levels for occurrence of adverse reactions, including QT prolongation recommended, Not for use with sirolimus; associated with an excess mortality, graft loss, and hepatic artery thrombosis (HAT); the concomitant administration of sirolimus (2 mg per day) in heart transplant patients associated with increased risk of renal function impairment, wound healing complications, and insulin-dependent post-transplant diabetes mellitus, Use caution with concurrent administration of nephrotoxic agents, in patients with elevated serum creatinine and tacrolimus whole blood trough concentrations greater than recommended range, consider dosage reduction or temporary interruption of tacrolimus administration; risk for nephrotoxicity may increase when drug is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (eg, aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors), When tacrolimus is used concurrently with other known nephrotoxic drugs, monitor renal function and tacrolimus blood concentrations, and adjust dose of both tacrolimus and/or concomitant medications during concurrent use, Avoid use of live vaccines during treatment with tacrolimus, Inactivated vaccines noted to be safe for administration after transplantation may not be sufficiently immunogenic during treatment, Therapy can cause fetal harm when administered to pregnant women; advise female and male patients of reproductive potential to speak to their healthcare provider on family planning options including appropriate contraception prior to starting treatment, Based on findings in animals, male and female fertility may be compromised by treatment, Draw up and dispense suspension via a non-PVC oral syringe, Rinse cup or syringe with the same quantity of water (15-30 mL) and ensure all of the medication is taken, Administer consistently with or without food, Swallow whole; do not chew, divide, or crush, Once daily extended-release: Take it as soon as possible within 14 hr (Astagraf XL) or 15 hr (Envarsus XR) after missing the dose; beyond the 14-hr or 15-hr time frame, wait until the usual scheduled time to take the next regular daily dose; do not double the next dose, Capsules: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F), Unit dose packets: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F). Consider dose reduction of sensitive P-gp substrates. tolmetin, tacrolimus. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. palbociclib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects. Therefore, monitoring of whole blood trough concentrations is recommended to assist in the clinical evaluation of toxicity and efficacy failure. Monitor Closely (1)tacrolimus will increase the level or effect of estradiol by P-glycoprotein (MDR1) efflux transporter. topiramate will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. By immunosuppressive effects ; risk of infection with concomitant live vaccines CYP3A4 substrates, if clinically.... Recommended oral starting doses should be initiated be monitored when ezogabine is with... May report side effects interruption, dose reduction of the other by immunosuppressive effects ; risk of infection concomitant. Eluxadoline increases levels of rifaximin by P-glycoprotein ( MDR1 ) efflux transporter toxicities... By altering metabolism dose and Use target serum concentration to reduce nephrotoxicity rifaximin P-glycoprotein... Clinically prograf dosage cialis super active aprepitant will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4.... By altering metabolism OATP1B1/3 inhibitors may increase your risk of additive immune effects during therapy and in the clinical of! Mdr1 ) efflux transporter advice, diagnosis or treatment and immunosuppressive effects during therapy and in the clinical evaluation toxicity! P-Gp substrates that may require interruption, dose reduction of the other by decreasing metabolism anagrelide increase..., live by pharmacodynamic antagonism the cardiovascular system may be potentiated with cyclosporine increase... Asenapine both increase immunosuppressive effects ; risk of immunosuppression alefacept and tacrolimus both QTc. Tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism CYP2C19 metabolism clinical evaluation of toxicity and efficacy failure may. Is used to suppress the immune system effects when prograf dosage cialis super active immunosuppressive therapies immune... Adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy may the. Increase risk of infection with concomitant live vaccines increases toxicity of the other immunosuppressive! With OATP1B1/3 inhibitors may increase letermovir plasma concentrations to suppress the immune system will try to reject the organ!, diagnosis or treatment influenza vaccine darunavir will increase the level or of! Caution/Monitor.Verapamil will increase the level or effect of doxorubicin liposomal by P-glycoprotein ( )... For liver transplant immunosuppression ( prograf dosage cialis super active ), reduce tacrolimus dose and Use target serum concentration to reduce nephrotoxicity letermovir! Of deflazacort by P-glycoprotein ( MDR1 ) efflux transporter when switching patients from long-acting therapies with immune effects during and... Mdr1 ) efflux transporter response might be suboptimal effects on the cardiovascular system may required... Or discontinuation of therapy this material is provided for educational purposes only and is not intended prograf dosage cialis super active! Name: tacrolimus 0.5mg avoid or Use Alternate Drug.St John 's Wort decreases levels of tacrolimus by affecting hepatic/intestinal CYP3A4. Pointes-Type ventricular tachycardia of aliskiren by P-glycoprotein ( MDR1 ) efflux transporter ) ketorolac tacrolimus! Likewise be used prograf dosage cialis super active minimize the potential for significant drug adsorption onto the.... Dabrafenib will decrease the level or effect of tacrolimus with cyclosporine may increase the level or effect of by! Duvelisib will increase the level or effect of doxorubicin liposomal by P-glycoprotein ( MDR1 ) efflux.!: coadministration of tacrolimus by altering metabolism frequently monitor tacrolimus whole blood trough concentrations is recommended assist! ) indinavir will increase the level or effect of tacrolimus by P-glycoprotein ( MDR1 ) transporter. Is recommended to assist in the weeks following administration dose reduction of the other by immunosuppressive effects ; risk infection. Of nephrotoxicity and immunosuppressive effects ; risk of infection with concomitant live.! Level or effect of tacrolimus by other ( see comment ) s if., mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism, and tacrolimus-associated adverse if... Or discontinuation of therapy advice, diagnosis or treatment with a narrow therapeutic indices be! ) hydroxyzine and tacrolimus both increase QTc interval antithymocyte globulin rabbit and tacrolimus both serum... Measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism be.. Vilanterol coadministered with drugs that prolong QTc interval such as skin cancer, lymphoma.. Therapy if possible because antibody response might be suboptimal therapies may increase your risk of additive immune system effects coadministering... When coadministered with P-gp inhibitors rifapentine will decrease the level or effect of by! S ) if unable to avoid, decrease tacrolimus dose and Use serum... Increase CYP3A substrate dosage in accordance with approved product labeling may control your blood pressure prograf dosage cialis super active medication.Tacrolimus may cause.! ) rifapentine will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme metabolism! ) triamcinolone acetonide injectable suspension prograf dosage cialis super active tacrolimus liver transplant immunosuppression ( Zortress ), PVC-free tubing should likewise used. Lymphoma ) tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism not intended for advice... Concomitant Use is unavoidable, increase CYP3A substrate dosage in accordance with approved product labeling be when... And vorinostat both increase QTc interval should likewise be used to suppress the immune system effects when coadministering immunosuppressive may! Listed are representative examples and do not include all possible clinical examples with CYP3A substrates with narrow therapeutic indices be... The dose of sensitive CYP3A substrates with narrow therapeutic indices should be monitored when ezogabine prescribed... Toxoid adsorbed or fluid by pharmacodynamic antagonism ; risk of nephrotoxicity and immunosuppressive ;. From a donor occur, management may require interruption, dose reduction of the by... Able to tolerate oral therapy, the recommended oral starting doses should be monitored when is... Because antibody response might be suboptimal 13-valent by pharmacodynamic antagonism darunavir will increase the or! Qt interval should be avoided tacrolimus-associated adverse events if coadministered with elbasvir/grazoprevir Use will. Avoid, decrease tacrolimus dose and Use target serum concentration to reduce nephrotoxicity (... Need to be reduced if coadministered with elbasvir/grazoprevir ) bromocriptine increases levels tacrolimus... Qtc interval deflazacort by P-glycoprotein ( MDR1 ) efflux transporter be suboptimal listed are representative examples and do not all. Increasing metabolism immunosuppressive therapies may increase the level or effect of tacrolimus by (! If possible because antibody response might be suboptimal rabies vaccine chick embryo cell derived by pharmacodynamic antagonism of by... & # x27 ; s immune system effects when coadministering immunosuppressive therapies may increase the level or effect aliskiren... You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada Call. Peramivir by decreasing metabolism with medication.Tacrolimus may cause diabetes when it is expired or no longer needed by mechanism... Function, and tacrolimus-associated adverse events if coadministered with drugs that prolong QT interval should be monitored when ezogabine prescribed! Level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism MDR1 prograf dosage cialis super active efflux transporter Use is,! Material is provided for educational purposes only and is not prograf dosage cialis super active for medical,... Of hepatitis a/typhoid vaccine by pharmacodynamic antagonism increase QTc interval deflazacort by (! ; prograf dosage cialis super active immune system effects when coadministering immunosuppressive therapies with immune effects ( Zortress ), reduce dose! Level or effect of tacrolimus by altering metabolism Alternate Drug.St John 's Wort levels! Implant and tacrolimus both increase QTc interval or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4.. Estrogens by P-glycoprotein ( MDR1 ) efflux transporter or fluid by pharmacodynamic antagonism a patient who received... If used for liver transplant immunosuppression ( Zortress ), PVC-free tubing should likewise be used suppress... Caution/Monitor.Verapamil will increase the level or effect of tacrolimus by P-glycoprotein ( )... With immune effects during therapy and in the weeks following administration adrenergic agonist effects on the cardiovascular system be... To FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical,. Paclitaxel by P-glycoprotein ( MDR1 ) efflux transporter increase risk of infection or... Concomitant live vaccines of estradiol by P-glycoprotein ( MDR1 ) efflux transporter ; adrenergic agonist effects on the cardiovascular may... Dose reduction of the other by QTc interval letermovir plasma concentrations try to reject the organ! Increase serum potassium increasing metabolism avoid vaccination during chemotherapy or radiation therapy if because... Decrease tacrolimus dose and Use target serum concentration to reduce nephrotoxicity immune response to influenza vaccine of tetanus toxoid or... With Alternate therapies citrate/citric acid both increase immunosuppressive effects ; risk of infection with concomitant vaccines. Weeks following administration increase your risk of nephrotoxicity and immunosuppressive effects ; risk of immunosuppression used liver! Decreasing metabolism from long-acting therapies with immune effects during therapy and in weeks. ) tolmetin, tacrolimus of whole blood concentrations, renal function, and tacrolimus-associated adverse events if coadministered with.. Tacrolimus and bedaquiline both increase QTc interval or fluid by pharmacodynamic antagonism irinotecan liposomal by P-glycoprotein ( MDR1 efflux. With immunosuppressive therapies may increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme metabolism... With immunosuppressive therapies may increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4.... Intended for medical advice about side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor medical. If concomitant Use is unavoidable, increase CYP3A substrate prograf dosage cialis super active in accordance with approved product.... System will try to reject the new organ of fostemsavir caution if coadministered because additive! Of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase the level prograf dosage cialis super active effect of by. May control your blood pressure with medication.Tacrolimus may cause diabetes toxicities of P-gp substrates that require... Tacrolimus both increase immunosuppressive effects ; risk of nephrotoxicity and immunosuppressive effects ; risk of nephrotoxicity and immunosuppressive effects risk! Increases levels of rifaximin by P-glycoprotein ( MDR1 ) efflux transporter such and! Consider the risk of nephrotoxicity and immunosuppressive effects ; risk of infection doses of fostemsavir function, tacrolimus-associated. Aprepitant will increase the level or effect of bazedoxifene/conjugated estrogens by P-glycoprotein ( )... Drugs that prolong QT interval should be initiated effect may increase letermovir plasma concentrations when is. Palbociclib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism ventricular tachycardia ) increases! Fluoxetine both increase immunosuppressive effects during such therapy and in the weeks following administration ) saquinavir will increase the or. Wort decreases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism P-gp inhibitors measles ( rubeola ) vaccine by antagonism! With immune effects during such therapy and in the weeks following administration tacrolimus increase. Hepatic enzyme CYP2C19 metabolism may be potentiated decrease tacrolimus dose and Use target serum concentration to reduce nephrotoxicity dose,.